Sector Gamma AS Sells 20,876 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sector Gamma AS lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 39.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,092 shares of the biopharmaceutical company’s stock after selling 20,876 shares during the quarter. Alnylam Pharmaceuticals makes up about 1.5% of Sector Gamma AS’s investment portfolio, making the stock its 23rd largest position. Sector Gamma AS’s holdings in Alnylam Pharmaceuticals were worth $6,143,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ALNY. Quent Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares during the period. Anchor Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $38,000. GAMMA Investing LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. Lindbrook Capital LLC lifted its position in shares of Alnylam Pharmaceuticals by 37.2% during the 4th quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 100 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 52.4% during the 3rd quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 311 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ALNY shares. Morgan Stanley cut their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 13th. Cantor Fitzgerald restated a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. HC Wainwright restated a “buy” rating and issued a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $215.88.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded down $0.40 during trading hours on Friday, reaching $143.31. 479,139 shares of the company were exchanged, compared to its average volume of 467,891. The company has a market capitalization of $18.05 billion, a P/E ratio of -40.26 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $218.88. The business has a 50 day moving average of $150.21 and a 200 day moving average of $165.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.68) EPS. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.